Additional Indices
Our technology has been validated in study after study and we continue to pursue active research to further new formulation development and confirm benefit in disease indices where we can have a positive impact.
Additional Indices Studies
NeOnc’s research has suggested that our NEO delivery platform can have an impact on the advancement of CNS-based tumors and disorders. As the company moves to commercialize its current NEO100 and NEO212 formulations for their respective disease models, acceptance of our delivery platform will help open the door to being to develop other durg conjugations of already accepted CNS therapeutics in order to provide them enhanced delivery and potentially greater efficacy.
A Growing Concern
The need for better treatment models for CNS-based diseases continues to grow dramatically due to population increase, aging, and toxic exposure. In a report published by the National Institutes of Health, a study looking at the global, regional, and national burden of neurological disease from 1906 to 2016 found that CNS-based diseases were the leading cause of disability-adjusted life years (DALYs) and the second leading cause of deaths when looked at as a category.
DALYs address the overall burden that disease places on a person by measuring the years of life lost due to premature mortality and the years lost due to time lived in states of less than total health. It is a more complete picture than just looking at the mortality rate of a disease. In a study that looked at the top fourteen causes of CNS-based disease, including cancers, the three most burdensome neurological disorders in the U.S., in terms of the absolute number of DALYs, were strokes at 3.58 million, Alzheimer’s disease, and other dementias at 2.55 million, and migraines at 2.40 million.
Based on this and many others, there is a large and increasing burden of neurological disorders in the U.S. The need to address these growing trends needs to happen at every level of the healthcare industry and government oversight groups to advance healthcare planning and resource allocation to prevent and reduce the burden of neurological disorders.
NeOnce recognizes this need and is committed to research and development to help develop viable solutions using its proprietary pharma-therapeutic delivery technology.
Future CNS Treatment Possibilities
By Enabling Greater Penetration of the BBB, NeOnc believes its NEO platform can turn existing
FDA-approved drugs into more effective treatments across a full range of CNS disorders. Potential areas of impact NeOnc is looking to explore include the following disease models:
- Parkinson’s Disease
- Bi-Polar Disorder
- Alzheimer’s
- Chronic Migraines
- Epilepsy
- Brain Metastases
- Autoimmune Disease
- Spinal Cord Injury
A Growing Market
Below is the most recent data on the growing market cost associated with three of the top non-cancer neurological disorders where NeOnce believes it may have the ability to impact the cost of treatment and the impact these diseases have on DALYs and the basic standard of living for patients.
